Aardvark Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AARD | DTC.CN | ABVC | ALDX | ALLR | ACTU | |
|---|---|---|---|---|---|---|
| Market cap | 27.57M | 25.50M | 26.69M | 39.06M | 17.18M | 20.34M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.5 | — | -2.3 | -2.4 | -1.3 | -0.6 |
| Price/book | 0.4 | 7.3 | 2.5 | 1.0 | 4.9 | 9.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −88.29% | −63.04% | −65.92% | −87.40% | −7.38% | −94.58% |
| Today | +2.44% | −1.47% | +1.51% | +4.32% | −4.42% | +5.69% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AARD news ›Mallinckrodt Loses $9.5M Award, Wins Delay In Airgas Drug
Mallinckrodt Loses $9.5M Award But Wins Delay In Airgas Drug Law360 Try our Advanced Search for more refined results The Practice of Law Deep News & Analysis Mallinckrodt Loses $9.5M Award, Wins Delay In Airgas Drug Law360 is on it, so you…
Aurora Innovation, Inc. (AUR) Securities Investigation Notice - Levi & Korsinsky
In its third quarter 2026 financial results, Aurora Innovation said supply chain bottlenecks had delayed its driverless truck targets. The Company stated that the production delays for its autonomous commercial trucks would push its…
ATEC SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Alphatec Holdings
Nov 02, 2026, 13:08 ET ATEC shares fell sharply after Alphatec Holdings cut its full-year 2026 revenue outlook to approximately $862 million, citing biologics, thoracolumbar, and international supply pressures. SueWallSt notifies investors…
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00…
Aardvark Therapeutics price target lowered to $2.50 from $6 at RBC Capital
RBC Capital lowered the firm’s price target on Aardvark Therapeutics (AARD) to $2.50 from $6 and keeps a Sector Perform rating on the shares. P... Aardvark Therapeutics price target lowered to $2.50 from $6 at RBC Capital RBC Capital…
FDA lifts hold on Aardvark Therapeutics IND application for ARD-101
Aardvark Therapeutics (AARD) announced that the FDA has lifted the clinical hold on the company’s investigational new drug application for ARD-1... FDA lifts hold on Aardvark Therapeutics IND application for ARD-101 Aardvark Therapeutics…
More from 1 other outlet
Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript
Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials October 23, 2026 8:00... Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From…
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek…
More from 2 other outlets
- The National Law Review DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
- TMX Newsfile AARD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
Aardvark Therapeutics, Inc. Announces Appointment of David Zhang as Class II Independent Director, Effective October 7, 2026
Aardvark Therapeutics, Inc. announced the appointment of David Zhang, Ph.D., MBA, as a Class II director, effective October 7, 2026. Dr. Zhang, age 58 will serve as an independent director. Brings... announced the appointment of David…
Transcript : Aardvark Therapeutics, Inc. - Special Call
Presentation Operator MessageOperator Good day. Thank you for standing by. Welcome to the Aardvark Therapeutics Update Call. [Operator Instructions] Please advise that today's conference will be... Transcript : Aardvark Therapeutics, Inc.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- globenewswire.com16
- prnewswire.com15
- marketscreener.com8
- markets.businessinsider.com5
- financialcontent.com4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 81 articles, not a forecast.